Literature DB >> 6386675

Avidities of hapten-specific antibodies when the responses are modulated by anti-carrier antibodies.

E Whited Collisson, B Andersson, E W Lamon.   

Abstract

Either alone or in combination with antibodies having specificity for the carrier erythrocyte, TNP-ORBC were injected i.p. into CBA/J mice. Five days later, their spleens were removed and evaluated for TNP-specific PFC. The spleens from animals receiving 19S antibody (IgM) with carrier specificity displayed 3-4-fold more direct and indirect hapten-specific PFC than control animals receiving the TNP-erythrocyte conjugate only. Animals receiving 7S antibodies (IgG) with carrier specificity displayed very little change in their direct PFC response to the hapten. However, the indirect response to the hapten was suppressed as much as 16-fold by carrier specific IgG. Evaluation by haptenic inhibition of the relative avidity of the antibodies being secreted by these cells revealed the following: the relative avidity of antibodies secreted by indirect PFC in the spleens of animals receiving TNP-ORBC only was approximately 20-fold higher than antibodies secreted by the direct PFC. The 3-4-fold potentiation of the hapten-specific PFC response by carrier-specific IgM antibody did not result in a change in relative avidity of direct or indirect PFC. IgG with carrier specificity did not change the relative avidity of the antibodies secreted by direct PFC having specificity for the hapten. However, evaluation of the remaining PFC in spleens from animals whose indirect hapten-specific PFC response had been suppressed by carrier-specific IgG revealed that the remaining PFC had a lower avidity than indirect PFC from animals receiving TNP-ORBC only. In other words, carrier-specific IgG selectively induced suppression of high avidity hapten-specific IgG antibody secreting cells.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6386675      PMCID: PMC1454929     

Source DB:  PubMed          Journal:  Immunology        ISSN: 0019-2805            Impact factor:   7.397


  26 in total

1.  VARIATIONS IN AFFINITIES OF ANTIBODIES DURING THE IMMUNE RESPONSE.

Authors:  H N EISEN; G W SISKIND
Journal:  Biochemistry       Date:  1964-07       Impact factor: 3.162

2.  Modulation of hapten-specific antibody responses with anticarrier antibody: I. Differential effects of IgM and IgG anticarrier on primary direct and indirect hapten-specific plaque-forming cells.

Authors:  E W Collisson; B Andersson; E W Lamon
Journal:  Proc Soc Exp Biol Med       Date:  1979-10

Review 3.  Cell selection by antigen in the immune response.

Authors:  G W Siskind; B Benacerraf
Journal:  Adv Immunol       Date:  1969       Impact factor: 3.543

Review 4.  Regulatory effect of antibody on the immune response.

Authors:  J W Uhr; G Möller
Journal:  Adv Immunol       Date:  1968       Impact factor: 3.543

5.  Effect of thymus-derived lymphocytes on amount and affinity of anti-hapten antibody.

Authors:  R K Gershon; W E Paul
Journal:  J Immunol       Date:  1971-03       Impact factor: 5.422

6.  Evidence for an immunoglobulin-dependent antigen-specific helper T cell.

Authors:  C A Janeway; R A Murgita; F I Weinbaum; R Asofsky; H Wigzell
Journal:  Proc Natl Acad Sci U S A       Date:  1977-10       Impact factor: 11.205

7.  Studies on antibody avidity at the cellular level. Effects of immunological paralysis and administered antibody.

Authors:  B Andersson; H Wigzell
Journal:  Eur J Immunol       Date:  1971-11       Impact factor: 5.532

8.  IgM complex receptors on subpopulations of murine lymphocytes.

Authors:  E W Lamon; B Andersson; H D Whitten; M M Hurst; V Ghanta
Journal:  J Immunol       Date:  1976-05       Impact factor: 5.422

9.  Plaque Formation in Agar by Single Antibody-Producing Cells.

Authors:  N K Jerne; A A Nordin
Journal:  Science       Date:  1963-04-26       Impact factor: 47.728

10.  Studies on the regulation of avidity at the level of the single antibody-forming cell. The effect of antigen dose and time after immunization.

Authors:  B Andersson
Journal:  J Exp Med       Date:  1970-07-01       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.